Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573641 | 1.00 | KMT2A (0.54) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL29147650 | 1.00 | KMT2A (0.54) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL20599568 | 0.96 | MEN1 (0.51) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| Ethylmalonate SCHEMBL29947022 | 0.89 | KMT2A (0.46) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL29946917 | 0.88 | KMT2A (0.46) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL28581241 | 0.87 | KMT2A (0.55) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL28916508 | 0.87 | KMT2A (0.55) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL28915732 | 0.87 | KMT2A (0.55) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL31673991 | 0.87 | KMT2A (0.53) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL18787688 | 0.85 | HSD17B10 (0.50) | KMT2AMEN1HSD17B10SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114901277-B | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117440813-A | EGFR degrading agents for treating brain or CNS cancer metastasis | C4医药公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2019112457-A1 | DOPAMINE-Β-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-06-13 | — | — | WO | disclosed |
| WO-2011114148-A1 | 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2011-09-22 | — | — | WO | disclosed |
| EP-0210883-B1 | Derivatives of penem | DAIICHI SEIYAKU CO (JP) | 1995-02-01 | — | — | EP | disclosed |
| US-5079357-A | Bactericides | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-01-07 | — | — | US | disclosed |
| US-4962202-A | PENICILLIN INTERMEDIATES | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0210883-A2 | Derivatives of penem | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396501-B2 | Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same | CXCR4, CXCL12, CXCR1 | KMT2A 3763/4885MEN1 3996/4885HSD17B10 2427/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | KMT2A 3763/4885MEN1 3996/4885HSD17B10 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.